Clinical Trials Browser

Phase 1/2 × Drug Therapy × 90 days × Clear all

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT07354061 2026-04-01

TD-ENSEMBLE

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Neoplasms

NCT07477444 2026-03-20

HER-OIC

Phase 1/2 Not yet recruiting

Gastrointestinal

Gastroesophageal Cancer

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT05214482 2026-03-03

A Study of AK112 in Advanced Malignant Tumors

Phase 1/2 Completed

Advanced Malignant Tumors

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05731947 2026-01-29

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence